Synbiotic loaded chitosan-Ca-alginate microparticles reduces inflammation in the TNBS model of rat colitis

Ivanovska, Tanja Petreska; Mladenovska, Kristina; Zhivikj, Zoran; Pavlova, Maja Jurhar; Gjurovski, Ivica; Ristoski, Trpe; Petrushevska-Tozi, Lidija

doi:10.1016/j.ijpharm.2017.05.049

Cited by 43 publications

(26 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, we evaluated the anti-colitis efficacy of BD-SNEDDS in parallel to BD-suspension. Using the TNBS-induced model, 67,68 we assessed the clinical symptoms including body weight loss, diarrhea, hematochezia, DAI, histological alterations, and shortened colons. The DAI score is a common indicator for the evaluation of severity of colitis, wherein a higher DAI score represents more discomfort conditions.…”

Section: Figurementioning

confidence: 99%

Self-nanoemulsfiying drug delivery system of bruceine D: a new approach for anti-ulcerative colitis

Dou¹,

Zhou²,

Wang³

et al. 2018

IJN

View full text Add to dashboard Cite

BackgroundBruceine D (BD) is a major bioactive component isolated from the traditional Chinese medicinal plant Brucea javanica which has been widely utilized to treat dysentery (also known as ulcerative colitis [UC]).MethodsTo improve the water solubility and absolute bioavailability of BD, we developed a self-nanoemulsifying drug delivery system (SNEDDS) composing of MCT (oil), Solutol HS-15 (surfactant), propylene glycol (co-surfactant) and BD. The physicochemical properties and pharmacokinetics of BD-SNEDDS were characterized, and its anti-UC activity and potential mechanism were evaluated in TNBS-induced UC rat model.ResultsThe prepared nanoemulsion has multiple beneficial aspects including small mean droplet size, low polydispersity index (PDI), high zeta potential (ZP) and excellent stability. Transmission electron microscopy showed that nanoemulsion droplets contained uniform shape and size of globules. Pharmacokinetic studies demonstrated that BD-SNEDDS exhibited enhanced pharmacokinetic parameters as compared with BD-suspension. Moreover, BD-SNEDDS significantly restored the colon length and body weight, reduced disease activity index (DAI) and colon pathology, decreased histological scores, diminished oxidative stress, and suppressed TLR4, MyD88, TRAF6, NF-κB p65 protein expressions in TNBS-induced UC rat model.ConclusionThese results demonstrated that BD-SNEDDS exhibited highly improved oral bioavailability and advanced anti-UC efficacy. In conclusion, our current results provided a foundation for further research of BD-SNEDDS as a potential complementary therapeutic agent for UC treatment.

show abstract

Section: Figurementioning

confidence: 99%

Self-nanoemulsfiying drug delivery system of bruceine D: a new approach for anti-ulcerative colitis

Dou¹,

Zhou²,

Wang³

et al. 2018

IJN

View full text Add to dashboard Cite

show abstract

“…Effect of synbiotic was more significant in the promotion of the lactobacilli growth in colitic rats than probiotic. 9 Sood and others in a multicenter, randomized, doubleblind, placebo-controlled trial in India (2009) included 147 patients with mild-to-moderate UC and allocated them into those receiving VSL # 3, a high potency probiotic, or placebo twice daily for 12 weeks. They were assessed at weeks 6 and 12 for three points or more decrease in the disease activity index.…”

Section: Discussionmentioning

confidence: 99%

Effect of Lactocare® Synbiotic on Disease Severity in Ulcerative Colitis: A Randomized Placebo-Controlled Double-Blind Clinical Trial

Amiriani

Rajabli

Faghani

et al. 2019

Middle East J Dig Dis

View full text Add to dashboard Cite

BACKGROUND Inflammatory bowel diseases are managed by different methods, which may not be well tolerated because of their side effects. Recently, pro-prebiotics are considered as a supplementary treatment in gastrointestinal diseases. In this study, the effect of Lactocare® (ZistTakhmir Company) was investigated on the disease severity in mild to moderate ulcerative colitis. METHODS In this randomized, double-blind clinical trial (Iranian Registry of Clinical Trials number: IRCT201407271264N5), 60 patients with mild to moderate ulcerative colitis were included. An 8-week trial was carried out comparing Lactocare® as a supplement with standard therapy against placebo. Simple Clinical Colitis Activity Index (SCCAI) was measured at baseline and after 8 weeks. Statistical analysis was performed using paired ttest to assess the temporal changes (before and after the treatment) in the mean of SCCAI in each group. Chi-square test was used to compare the response rates. Odds ratios (OR) and the 95% confidence intervals (95%CI) were also calculated. p values of less than 0.05 were considered significant. RESULTS A significant decreased mean SCCAI was seen in the intervention group (4.56 ± 2.56) vs. placebo group (6.54 ± 2.47) (p < 0.05). Response to treatment was seen in 64.3% of the treatment group vs. 47% in the placebo group (p = 0.18). Response to treatment was observed in 90.9% of patients with ulcerative colitis for more than 5 years compared with 44.4% of the control group (p = 0.01). CONCLUSION Regarding the effectiveness of pre-probiotics in mitigating symptoms in patients with ulcerative colitis, it could be suggested to try pre-probiotics in the standard treatment particularly in those with more than five years ofthe disease.

show abstract

“…This combination of the probiotic and the prebiotic (oligofructose-enriched inuline) was also tested after its encapsulation in chitosan-Ca-alginate microparticles, which showed the best anti-inflammatory effects (Ivanovska et al, 2017). Thus, even though in vitro studies show that probiotics on their own may exert beneficial effects in inflammatory conditions, a currently hot line of research in preclinical studies is to optimize their in vivo effects, mainly through the combination (after encapsulation or not) with other compounds (prebiotics, nutrients, nutraceuticals…).…”

Section: Evidence From Animal Modelsmentioning

confidence: 99%

Probiotics in digestive, emotional, and pain-related disorders

Román

Abalo

Marco

et al. 2018

Behavioural Pharmacology

View full text Add to dashboard Cite

In recent years, interest in the relationship between gut microbiota and disease states has grown considerably. Indeed, several strategies have been employed to modify the microbiome through the administration of different diets, by the administration of antibiotics or probiotics, or even by transplantation of feces. In the present manuscript, we focus specifically on the potential application of probiotics, which seem to be a safe strategy, in the management of digestive, pain, and emotional disorders. We present evidence from animal models and human studies, notwithstanding that translation to clinic still deserves further investigation. The microbiome influences gut functions as well as neurological activity by a variety of mechanisms, which are also discussed. The design and performance of larger trials is urgently needed to verify whether these new strategies might be useful not only for the treatment of disorders affecting the gastrointestinal tract but also in the management of emotional and pain disorders not directly related to the gut.

show abstract

Synbiotic loaded chitosan-Ca-alginate microparticles reduces inflammation in the TNBS model of rat colitis

Cited by 43 publications

References 39 publications

Self-nanoemulsfiying drug delivery system of bruceine D: a new approach for anti-ulcerative colitis

Self-nanoemulsfiying drug delivery system of bruceine D: a new approach for anti-ulcerative colitis

Effect of Lactocare® Synbiotic on Disease Severity in Ulcerative Colitis: A Randomized Placebo-Controlled Double-Blind Clinical Trial

Probiotics in digestive, emotional, and pain-related disorders

Contact Info

Product

Resources

About